Thimerosal

U.S. Releases $600 Million to Gavi After Pact to Phase Out Mercury-Containing Vaccines

The move conditions U.S. support on Gavi’s pledge to transition away from thimerosal, increases U.S. oversight, excludes U.S. funding for WHO.